Detecting Cancer Patents (Class 435/6.14)
  • Patent number: 11987849
    Abstract: This application relates to a composition for diagnosis of leptospirosis and a method for diagnosis of leptospirosis by real-time PCR. For example, the application relates to a pair of primers of SEQ ID NOS: 1 and 2 and a probe of SEQ ID NO: 3, a kit for diagnosis of leptospirosis, comprising the diagnostic composition, and a method for providing information for diagnosis of leptospirosis are provided. The composition and the method can specifically detect L. interrogans IS 1500 gene and exhibit excellent accuracy and sensitivity, compared to conventional well-known detection methods. Thus, the simple method through real-time PCR using the composition allows the quick and accurate diagnosis of leptospirosis.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: May 21, 2024
    Assignee: Industry-Academic Cooperation Foundation, Chosun University
    Inventors: Dong Min Kim, You Mi Lee, Choon Mee Kim
  • Patent number: 11989932
    Abstract: Systems and methods are provided for color-coded visualization to aid in diagnosis and prognosis of Alzheimer's disease (AD). The color-coded visualization mechanism can be driven by an integrated machine learning (ML) model, which can take as its inputs neuroimaging (e.g., magnetic resonance imaging (MRI), positron emission tomography (PET)) data, neuropsychological test scores, the cerebrospinal fluid (CSF) biomarker, and/or risk factors. With these inputs, the ML model can generate a color-coded visualization of the disease state.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: May 21, 2024
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Malek Adjouadi, Mohammad Eslami, Solale Tabarestani
  • Patent number: 11977075
    Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 7, 2024
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventor: Yuval Shaked
  • Patent number: 11971411
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 30, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
  • Patent number: 11965212
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: April 23, 2024
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • Patent number: 11957739
    Abstract: The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 16, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adam Bass, Haisheng Zhang
  • Patent number: 11953506
    Abstract: Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: April 9, 2024
    Assignee: MOLOGIC LIMITED
    Inventors: Gita Parekh, Paul Davis
  • Patent number: 11944708
    Abstract: The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: April 2, 2024
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Shihe Hou
  • Patent number: 11948297
    Abstract: A racially unbiased mammogram analyzer includes an interface for receiving mammograms; a processor for extracting features of mammograms of general population; a processor for extracting features of mammograms of a specific race. In one embodiment, the general population mammogram features are represented by middle layers of a CNN and the race specific features are represented by the end layer of the CNN network. In one embodiment, the race specific layers of CNN change dynamically according to the race indication done explicitly. In one embodiment the race specific layers of CNN change dynamically according to the race indication given by race indication processor. In one embodiment, the race indications are computed by a network of parallel variational autoencoder networks. In one embodiment, the race indicator computes race specific information to the CNN and are provided by variational autoencoders.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: April 2, 2024
    Assignee: MedCognetics, Inc.
    Inventors: Timothy Cogan, Richard Stubblefield, Lakshman Tamil
  • Patent number: 11939574
    Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 26, 2024
    Assignee: AUGMANITY NANO LTD
    Inventors: Anastasia Shapiro, Ido Bachelet, Yaniv Amir, Erez Lavi, Danielle Karo-Atar
  • Patent number: 11926820
    Abstract: This disclosure describes methods and compositions for protein and peptide sequencing.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 12, 2024
    Assignee: Google LLC
    Inventors: Annalisa Marie Pawlosky, Michael Gibbons, Shirley Jing Shao, Marc Berndl, Michelle Therese Hoerner Dimon, Ali Bashir, Lauren Schiff
  • Patent number: 11913939
    Abstract: Methods and systems for performing assays in compartmentalized nano-volumes to screen for functional bispecific or multispecific biologics, including: providing a plurality of at least two distinct types of cells, wherein two or more first-type cells are engineered to express substantially a single genetic-variant per cell for a bispecific or multispecific biologic in a secreted form, wherein two or more second-type cells are selected or engineered to produce a positive reporter molecule signal that is triggered by a functional variant of the said biologic expressed by a first-type cell; providing a plurality of compartmentalized nano-volumes, wherein two or more nano-volumes are each provided with substantially one first-type cell, and one or more second-type cell(s); incubating the said nano-volumes over a period of time to allow the expression and secretion of the said biologics inside the said nano-volumes; collecting data representing the positive reporter molecule signal triggered by secreted biologics
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: February 27, 2024
    Assignee: Amberstone Biosciences, Inc.
    Inventors: George Guikai Wu, Yonglei Shang
  • Patent number: 11913012
    Abstract: The present disclosure provides methods for generating induced cardiomyocytes and/or inducing a cardiomyocyte phenotype in cells in vivo or in vitro, such as by expression of ASCL1 or MYF6 and MYOCD. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides selected from ASCL1, MYF6, MYOCD, MEF2C, and TBX5. It further provides compositions comprising induced cardiomyocytes and provides methods of treating a heart condition, such as myocardial infarction. The disclosure also provides engineered myocardin proteins with an internal deletion, vectors encoding such engineered mycocardins, and methods of use thereof.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: February 27, 2024
    Assignee: Tenaya Therapeutics, Inc.
    Inventors: Huanyu Zhou, Laura Lombardi
  • Patent number: 11913072
    Abstract: Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: February 27, 2024
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Cindy Cheung, Grantland Hillman, Xiaoju Max Ma, Chitra Manohar, Lily Wong
  • Patent number: 11885733
    Abstract: Systems and methods for modeling and detecting white blood cell population dynamic for diagnosis and treatment, e.g., of acute coronary syndrome or leukocytosis.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: January 30, 2024
    Assignee: The General Hospital Corporation
    Inventors: John M. Higgins, Anwesha Chaudhury
  • Patent number: 11884981
    Abstract: One aspect of the invention is a method for amplifying alpha globin genes HBA1, HBA2 and HBA12 in a single PCR tube to determine an HBA genotype of a subject. This method employs five primers selected to accurate and sensitively identify the HBA1, HBA2, and HBA12, a gene found at a higher frequency in citizens of Saudi Arabia, by accurately annealing to nucleic acids in a biological sample and simultaneously amplifying sequences encoding the alpha globin genes. This invention includes a procedure and required reagents for the amplification of alpha globin genes in a single PCR tube.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: January 30, 2024
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: J. Francis Borgio, Sayed Abdulazeez, Fahd A. Al-Muhanna, Amein Kadhem Al-Ali
  • Patent number: 11879150
    Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient would be advantageous. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: January 23, 2024
    Assignees: YAKULT HONSHA CO., LTD., KINKI UNIVERSITY
    Inventors: Kazuto Nishio, Yoshihiko Fujita
  • Patent number: 11873535
    Abstract: Described herein are methods and kits for authentication of botanical DNA fragments isolated from processed botanical products, including dietary supplements or nutraceutical compositions including botanical extracts.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: January 16, 2024
    Assignee: HERBALIFE INTERNATIONAL OF AMERICA, INC.
    Inventors: Zhengfei Lu, Silva Babajanian, Yanjun Zhang, Peter Chang, Gary Swanson, Maria Rubinsky
  • Patent number: 11872554
    Abstract: A microfluidic device includes an inlet port configured to receive a sample, a first reaction chamber fluidically coupled to the inlet port, a first pump fluidically coupled to the inlet port, a second pump fluidically coupled to a mixing chamber, a metering channel fluidically coupled to the first reaction chamber and to the mixing chamber, and one or more second reaction chambers fluidically coupled to the mixing chamber. The first pump is configured to move fluid from the inlet port to the first reaction chamber and from the first pump to the inlet port. The second pump is configured to move fluid from the second pump to the mixing chamber, from the first reaction chamber to the mixing chamber, and from the mixing chamber to the one or more second reaction chambers.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: January 16, 2024
    Assignee: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
    Inventors: Alexander Schenk zu Schweinsberg, Austin Matthew Derfus, Justin Davidson, Karthikeyan Kumaravadivelu, Maulik Vinod Patel, Olaf Piepenburg, Catherine Jean Greenwood, Oliver Nentwich
  • Patent number: 11873341
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 16, 2024
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
  • Patent number: 11866630
    Abstract: A quantum dot including a core including a first semiconductor nanocrystal including a Group III-V compound; and a semiconductor nanocrystal shell disposed on the core, the semiconductor nanocrystal shell including zinc, tellurium, and selenium, wherein the quantum dot does not include cadmium, and the semiconductor nanocrystal shell has a mole ratio of tellurium to selenium of less than about 0.025:1, a composition including the quantum dot, a quantum dot-polymer composite, a patterned layer including the composite, and an electronic device including the patterned layer.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: January 9, 2024
    Assignee: SAMSUNG DISPLAY CO., LTD.
    Inventors: Taekhoon Kim, Shin Ae Jun, Yong Wook Kim, Tae Gon Kim, Garam Park
  • Patent number: 11851709
    Abstract: The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: December 26, 2023
    Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL D'HEBRON, FUNDACIÓN SOLTI, FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA, HOSPITAL CLÍNIC DE BARCELONA
    Inventors: Aleix Prat Aparicio, Javier Cortés Castán, Antonio Llombart Cussac
  • Patent number: 11845975
    Abstract: The present disclosure provides a body fluid extract comprising micro RNA.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: December 19, 2023
    Assignee: Craif Inc.
    Inventors: Takao Yasui, Daiki Takeshita, Yoshinobu Baba
  • Patent number: 11845080
    Abstract: A heating system for an EWOD device using a single, spatially-structured temperature control element, used to create a zone with a specific temperature profile. The heating system uses multiple contact regions between the temperature control element and the device. One or more contact regions are separated from the temperature control element by one or more thermally resistive layers that restrict heat flow from the temperature control element to the device, and further restrict lateral flow of heat between adjacent contact regions. The heating system can use materials with different thermal resistance to alter the heat flow to different regions. The spatial location of the contact regions is also used to determine the temperature profile within the device. The device has an optional temperature control element which offsets the low temperature point from the inlet temperature. This invention includes methods to process multiple droplets within the multiple temperature zones.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: December 19, 2023
    Assignee: Sharp Life Science (EU) Limited
    Inventor: Phillip Mark Shryane Roberts
  • Patent number: 11847817
    Abstract: Methods and systems for automated assessment of spermatogenesis. Embodiments disclosed herein relate to drug development and testicular toxicity in safety evaluation studies, and more particularly to automatic assessment of spermatogenesis through a staging of seminiferous tubules using Artificial Intelligence/deep learning methods. A method disclosed herein includes detecting the seminiferous tubules by analyzing a testes tissue specimen and mapping the seminiferous tubules to detect and segment germ cells. The method includes classifying the seminiferous tubules into respective stages based on the segmented germ cells. The method further includes categorizing the seminiferous tubules into a normal category and an abnormal category based on the segmented germ cells. The method further includes categorizing the testes tissue specimen into the normal category and the abnormal category based on the classification of the seminiferous tubules for toxicity analysis.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: December 19, 2023
    Assignee: AIRAMATRIX PRIVATE LIMITED
    Inventors: Rohit, Pranab Samanta
  • Patent number: 11840733
    Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 12, 2023
    Assignee: GENCURIX INC.
    Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
  • Patent number: 11840735
    Abstract: This document provides methods and materials for identifying malignant skin lesions (e.g., malignant pigmented skin lesions). For example, methods and materials for using quantitative PCR results and correction protocols to reduce the impact of basal keratinocyte contamination on the analysis of test sample results to identify malignant skin lesions are provided.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: December 12, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Alexander Meves, Ekaterina M. Nikolova
  • Patent number: 11828768
    Abstract: The present invention relates to a device and a method for qualitative and quantitative analysis of heavy metals and more particularly provides a device and a method for qualitative and quantitative analysis of heavy metals utilizing a rotary disc system.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 28, 2023
    Inventors: Byung Hyun Park, Byoung Hyoun Kim, Dong Hyun Kim, Su Youn Han
  • Patent number: 11821040
    Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: November 21, 2023
    Assignee: Nanomed Diagnostics BV
    Inventors: Willem Frederik Rurup, Loes Irene Segerink, Roderik Adriaan Kraaijenhagen, Herbert Michael Pinedo, Albert Van Den Berg, Renske Daniëla Maria Steenbergen, Jacobus Adrianus Nieuwenhuijzen, Idris Bahce, Geert Kazemier
  • Patent number: 11821037
    Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: November 21, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Daniel R. Salomon, Sunil M. Kurian, Steven R. Head
  • Patent number: 11821046
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Zika virus nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 21, 2023
    Assignee: Gen-Probe Incorporated
    Inventors: Kui Gao, Jeffrey M. Linnen
  • Patent number: 11807892
    Abstract: One aspect of the invention provides a system for drug discovery, drug development, drug screening, or drug validation. The system includes: a sample chamber comprising a target protein and a drug candidate that may interfere with the target protein in the sample chamber, wherein the sample chamber is configured to: detect one or more of the following: (a) interference between the drug candidate the target protein and/or (b) one or more dynamics of the drug candidate on the target protein, wherein the one or more dynamics comprise affinity of the drug candidate to the target protein, and select the drug candidate if one or more desirable dynamics is detected. The system includes one or more immobilized surfaces and is configured to detect interactions between the drug candidate and the target protein at the single-molecule level.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Nanobiosym, Inc.
    Inventor: Anita Goel
  • Patent number: 11807895
    Abstract: A method for detecting oncogenic growth and viability, and/or degree of cellular transformation and/or identifying an agent that inhibits cellular transformation is disclosed. The method including: providing a cellular sample, such as a sample of cells obtained from a subject or a cell line; culturing the cellular sample in low attachment conditions; and detecting growth and7or cell viability of the sample, wherein increased growth relative and/or viability relative to a control or control level indicative of basal growth and/or viability indicates cellular transformation. In some embodiments, the method includes introducing a n expression vector into cells of the cellular sample, wherein the expression vector comprises a gene product expression sequence being tested for transformation ability. In some embodiments the cellular sample is contacted with a test agent and growth and/or cell viability of the sample is determined to determine if the agent inhibits transformation.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: November 7, 2023
    Assignees: THE BROAD INSTITUTE, INC., DANA FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Asaf Rotem, Kevin Struhl, Paul Blainey, Liyi Xu
  • Patent number: 11786872
    Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 17, 2023
    Assignees: UNITED KINGDOM RESEARCH AND INNOVATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
  • Patent number: 11788129
    Abstract: A GAPDH nucleic acid detection kit includes a primer set for detecting GAPDH nucleic acid. The primer set for detecting GAPDH nucleic acid includes a forward inner primer for GAPDH nucleic acids, a forward outer primer for GAPDH nucleic acids, a backward inner primer for GAPDH nucleic acids and a backward outer primer for GAPDH nucleic acids. The primer set for detecting GAPDH nucleic acid is used in a loop-mediated isothermal amplification (LAMP).
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: October 17, 2023
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Min-Yuan Chou, Kuang-Chi Cheng, Ming-Hua Yang, Jiun-Lin Guo
  • Patent number: 11788084
    Abstract: The present invention relates to the field of biotechnologies and in particular to the use of a nucleotide sequence having transcription promoter activity in prokaryotic and eukaryotic cell systems.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 17, 2023
    Assignee: UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO
    Inventors: René Massimiliano Marsano, Antonio Palazzo
  • Patent number: 11781153
    Abstract: A new use of OsDGD2? gene in breeding of male sterile rice materials is disclosed. The OsDGD2? gene deletion mutant created by technologies such as CRISPR/Cas9 gene editing is stable in male sterility, with no negative impact on female fertility and other traits (such as photosynthesis), making it uniquely superior in cross breeding and utilization of heterosis.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: October 10, 2023
    Assignee: Zhejiang University
    Inventors: Qingyao Shu, Rasbin Basnet
  • Patent number: 11760995
    Abstract: Provided is a PCR primer pair, comprising: a first primer and a second primer, wherein the first primer comprises a first specific sequence and a first random sequence; the first specific sequence is located on 3? end of the first primer, and the first random sequence is located on 5? end of the first primer; the second primer comprises a second specific sequence and a second random sequence, the second specific sequence is located on 3? end of the second primer, and the second random sequence is located on 5? end of the second primer; moreover, the first specific sequence and the second specific sequence are an upstream primer and a downstream primer directed to a target sequence respectively, and the first random sequence and the second random sequence are inverse complementary.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 19, 2023
    Assignee: MGI TECH CO., LTD.
    Inventors: Lin Yang, Ya Gao, Guodong Huang, Yicong Wang, Yuqian Wang, Yanyan Zhang, Fang Chen, Na Zhong, Hui Jiang, Xun Xu
  • Patent number: 11753616
    Abstract: The present application is to provide a composition and method for stabilizing and maintaining the viability of hardy microorganisms from sample collection to downstream analysis. In particular, there is a method for preserving viable hardy bacteria, such as Mycobacteria, Bacillus anthracis, or Clostridium difficile, in a biological sample, comprising contacting the biological sample with a stabilization composition, wherein the stabilization composition comprises a chelating agent, a denaturing, a salt and has a pH between about 6 and about 11.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: September 12, 2023
    Assignee: DNA Genotek, Inc.
    Inventors: H. Chaim Birnboim, Cassandra Kelly-Cirino, Bitapi Ray, Jacques Oscar Everard Niles, Olle Maarten de Bruin
  • Patent number: 11747335
    Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: September 5, 2023
    Assignee: University of Vermont And State Agriculture College
    Inventor: David Schneider
  • Patent number: 11738033
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: August 29, 2023
    Assignee: EIRGEN PHARMA LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Patent number: 11737993
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 29, 2023
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Patent number: 11730790
    Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 22, 2023
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jonathan Barasch, Andong Qiu
  • Patent number: 11726090
    Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 15, 2023
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, QUEEN MARY UNIVERSITY OF LONDON
    Inventors: Christoph Schröder, Jörg Hoheisel, Tatjana Crnogorac-Jurcevic
  • Patent number: 11726039
    Abstract: Provided are methods, for selectively analyzing a cell sample. Viable cells are dyed with a membrane-permeable fluorescent dye, and nonviable cells are dyed with a membrane-impermeable fluorescent quenching dye. The cells are illuminated to cause fluorescent emission from the membrane-permeable fluorescent dye in the viable cells and the membrane-impermeable fluorescent quenching dye in the non-viable cells. The cells are then quenched for at least a portion of fluorescence of the membrane-permeable fluorescent dye in the nonviable cells by the membrane-impermeable fluorescent quenching dye. The cells are then analyzed for viable and nonviable cells.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 15, 2023
    Assignee: SageMedic Corporation
    Inventors: Ekaterina Moroz, Christian Apfel, Kraig K. Anderson
  • Patent number: 11697848
    Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: July 11, 2023
    Assignee: Cellular Biomedicine Group, Inc.
    Inventors: Fang Liu, Liping Lan, Yutian Wei, Xun Ye, Li Zhang, Jiaqi Huang, Yihong Yao
  • Patent number: 11685956
    Abstract: A method for detecting a methylated genomic locus is provided. In certain embodiments, the method comprises: a) treating a nucleic acid sample that contains both unmethylated and methylated copies of a genomic locus with an agent that modifies cytosine to uracil to produce a treated nucleic acid; b) amplifying a product from the treated nucleic acid using a first primer and a second primer, wherein the first primer hybridizes to a site in the locus that contain methylcytosines and the amplifying preferentially amplifies the methylated copies of the genomic locus, to produce an amplified sample; and c) detecting the presence of amplified methylated copies of the genomic locus in the amplified sample using a flap assay that employs an invasive oligonucleotide having a 3? terminal G or C nucleotide that corresponds to a site of methylation in the genomic locus.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: June 27, 2023
    Assignee: Exact Sciences Corporation
    Inventors: Graham P. Lidgard, Michael J. Domanico, Hatim Allawi, Hongzhi Zou
  • Patent number: 11674957
    Abstract: Enantiomeric pairs of molecular wires comprised of oligomeric nucleic acids, wherein the oligomers of each wire possess identical nucleobase pair sequences and thus identical conductivity as between wires, are constructed and used to sense biological or chemical entities of interest at the cellular or molecular level. The oligomeric molecular wires conduct voltage inputs to sensing subsystem integrated circuitry, either from an electrostatic potential arising from a targeting agent (i.e., a capture agent) binding to an intended biological or chemical target molecule, or from an electrostatic potential associated with a reference molecule that has non-specific interactions with the environment. The chirality of the oligomers imparts selectivity to either the targeting agent or the reference molecule during assembly of the sensing subsystem.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: June 13, 2023
    Assignee: VELANIDI TECHNOLOGIES LLC
    Inventors: Jane Ni, David Shykind, Devin Wiley
  • Patent number: 11657896
    Abstract: Systems and methods disclosed for recommending beauty products for a subject by using a DNA sequencer to generate genetic information; aggregating genetic information, beauty trend data, and cosmetic product response from a patient population; deep learning with a computer to generate at least one computer implemented classifier that predicts matching beauty products based on the genetic information, beauty trend data, and cosmetic product response from a patient population; and recommending one or more beauty products for the subject.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 23, 2023
    Inventor: Ha Tran
  • Patent number: 11649481
    Abstract: Embodiments of the methods and compositions provided herein relate to the selective cleavage of target nucleic acids. Some embodiments include recombinase-mediated selective cleavage of target nucleic acids with single-stranded nucleic acid probes and a recombinase. Some embodiments also include the enrichment of non-target nucleic acids in a sample by selective cleavage of target nucleic acids in the sample, and removal of the cleaved target nucleic acids from the sample.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 16, 2023
    Assignee: Illumina, Inc.
    Inventor: Clifford Lee Wang